PURPOSE: To define demographic and therapeutic associations with the risk of breast cancer in children treated for Hodgkin's disease (HD), particularly the frequency and interval to the development of contralateral breast cancer. METHODS AND MATERIALS: All 398 female patients (<19 years) treated for HD in five institutions during the accrual period were evaluated. Mean follow-up was 16.9 years. The standardized incidence ratio (SIR) was calculated as the ratio of the observed number of cases to the expected number of cases, estimated using age-matched controls from the Surveillance, Epidemiology, and End Results database. RESULTS: A total of 29 women developed breast cancer (25 invasive, 4 ductal carcinoma in situ; SIR, 37.25; 95% confidence interval, 24.96-53.64). Time to diagnosis was 9.4 to 36.1 years. Cumulative incidence was 24% at 30 years. Ten patients (34%) had bilateral disease (9 metachronous, 1 synchronous). The interval to contralateral breast cancer was 12 to 34 months. On univariate analysis, significant variables included stage of HD, mantle radiation dose, pelvic radiation (protective), and follow-up time. On multivariate analysis, early stage and older age at diagnosis of HD (<or=12 vs. >12 years) were significant predictors of secondary breast cancer. CONCLUSIONS: Women surviving pediatric HD were found to have a 37-fold increase in the risk of breast cancer and a high likelihood of rapidly developing bilateral disease. Early-stage HD and age greater than 12 years at diagnosis of HD were independent risk factors. Higher radiation doses may augment risk, and pelvic radiation may be protective. Breast cancer screening methodology and frequency, plus the role of prophylaxis in patients with unilateral disease, require definition.
PURPOSE: To define demographic and therapeutic associations with the risk of breast cancer in children treated for Hodgkin's disease (HD), particularly the frequency and interval to the development of contralateral breast cancer. METHODS AND MATERIALS: All 398 female patients (<19 years) treated for HD in five institutions during the accrual period were evaluated. Mean follow-up was 16.9 years. The standardized incidence ratio (SIR) was calculated as the ratio of the observed number of cases to the expected number of cases, estimated using age-matched controls from the Surveillance, Epidemiology, and End Results database. RESULTS: A total of 29 women developed breast cancer (25 invasive, 4 ductal carcinoma in situ; SIR, 37.25; 95% confidence interval, 24.96-53.64). Time to diagnosis was 9.4 to 36.1 years. Cumulative incidence was 24% at 30 years. Ten patients (34%) had bilateral disease (9 metachronous, 1 synchronous). The interval to contralateral breast cancer was 12 to 34 months. On univariate analysis, significant variables included stage of HD, mantle radiation dose, pelvic radiation (protective), and follow-up time. On multivariate analysis, early stage and older age at diagnosis of HD (<or=12 vs. >12 years) were significant predictors of secondary breast cancer. CONCLUSIONS:Women surviving pediatric HD were found to have a 37-fold increase in the risk of breast cancer and a high likelihood of rapidly developing bilateral disease. Early-stage HD and age greater than 12 years at diagnosis of HD were independent risk factors. Higher radiation doses may augment risk, and pelvic radiation may be protective. Breast cancer screening methodology and frequency, plus the role of prophylaxis in patients with unilateral disease, require definition.
Authors: Lois B Travis; Deirdre Hill; Graça M Dores; Mary Gospodarowicz; Flora E van Leeuwen; Eric Holowaty; Bengt Glimelius; Michael Andersson; Eero Pukkala; Charles F Lynch; David Pee; Susan A Smith; Mars B Van't Veer; Timo Joensuu; Hans Storm; Marilyn Stovall; John D Boice; Ethel Gilbert; Mitchell H Gail Journal: J Natl Cancer Inst Date: 2005-10-05 Impact factor: 13.506
Authors: J Yahalom; J A Petrek; P W Biddinger; S Kessler; D D Dershaw; B McCormick; M P Osborne; D A Kinne; P P Rosen Journal: J Clin Oncol Date: 1992-11 Impact factor: 44.544
Authors: A B Miller; G R Howe; G J Sherman; J P Lindsay; M J Yaffe; P J Dinner; H A Risch; D L Preston Journal: N Engl J Med Date: 1989-11-09 Impact factor: 91.245
Authors: Jean L Nakamura; Connie Phong; Emile Pinarbasi; Scott C Kogan; Scott Vandenberg; Andrew E Horvai; Bruce A Faddegon; Dorothea Fiedler; Kevan Shokat; Benjamin T Houseman; Richard Chao; Russell O Pieper; Kevin Shannon Journal: Cancer Res Date: 2011-01-01 Impact factor: 12.701
Authors: Lois B Travis; Andrea K Ng; James M Allan; Ching-Hon Pui; Ann R Kennedy; X George Xu; James A Purdy; Kimberly Applegate; Joachim Yahalom; Louis S Constine; Ethel S Gilbert; John D Boice Journal: J Natl Cancer Inst Date: 2012-02-06 Impact factor: 13.506
Authors: G Mariscotti; M Durando; G Ghione; A Luparia; E Regini; C Alfieri; P P Campanino; P Gavarotti; E Brignardello; G Gandini Journal: Radiol Med Date: 2012-08-08 Impact factor: 3.469
Authors: Elena B Elkin; Michelle L Klem; Anne Marie Gonzales; Nicole M Ishill; David Hodgson; Andrea K Ng; Lawrence B Marks; Joanne Weidhaas; Gary M Freedman; Robert C Miller; Louis S Constine; Sten Myrehaug; Joachim Yahalom Journal: J Clin Oncol Date: 2011-05-16 Impact factor: 44.544
Authors: M Jacob Adams; Ann Dozier; Roy E Shore; Steven E Lipshultz; Ronald G Schwartz; Louis S Constine; Thomas A Pearson; Marilyn Stovall; Paul Winters; Susan G Fisher Journal: Cancer Epidemiol Biomarkers Prev Date: 2010-01 Impact factor: 4.254
Authors: Ava Kwong; L P Wong; H N Wong; F B F Law; E K O Ng; Y H Tang; W K Chan; D T K Suen; C Choi; L S Ho; K H Kwan; M Poon; T T Wong; K Chan; S W W Chan; M W L Ying; W C Chan; E S K Ma; J M Ford; D W West Journal: Hugo J Date: 2010-04-10
Authors: Laura Cella; Raffaele Liuzzi; Mario Magliulo; Manuel Conson; Luigi Camera; Marco Salvatore; Roberto Pacelli Journal: Radiat Oncol Date: 2010-05-11 Impact factor: 3.481